Atrial Fibrillation Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Atrial Fibrillation stocks.

Atrial Fibrillation Stocks Recent News

Date Stock Title
Oct 2 ITGR Integer Holdings: More Than Re-Rated Here
Oct 2 ITGR Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028
Oct 2 ITGR Navigating 6 Analyst Ratings For Integer Holdings
Oct 2 BMY STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
Oct 2 ITGR Integer sells non-medical business for $50M
Oct 2 MDT Down More Than 50%, Is DexCom Stock a Bargain Now?
Oct 1 BMY PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Oct 1 ITGR ITGR Shares Gain on the Divestiture of Its Non-Medical Business Line
Oct 1 BMY A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
Oct 1 MDT Reasons to Retain Medtronic Stock in Your Portfolio Now
Oct 1 BMY BMS and Prime ink potential $3.5bn deal to develop T cell therapies
Oct 1 BMY Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
Oct 1 MDT Medtronic plc (NYSE:MDT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Oct 1 BMY 5 FDA decisions to watch in the fourth quarter
Oct 1 BMY Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
Sep 30 BMY Bristol Myers gets $6.4B Celgene CVR case dismissed: report
Sep 30 BMY Sector Update: Health Care Stocks Advance Late Afternoon
Sep 30 BMY US Judge Dismisses $6.4 Billion Suit Against Bristol Myers Over Delay in Drug Approvals
Sep 30 BMY Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Sep 30 BMY Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Atrial Fibrillation

Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain. The disease is associated with an increased risk of heart failure, dementia, and stroke. It is a type of supraventricular tachycardia.High blood pressure and valvular heart disease are the most common alterable risk factors for AF. Other heart-related risk factors include heart failure, coronary artery disease, cardiomyopathy, and congenital heart disease. In the developing world valvular heart disease often occurs as a result of rheumatic fever. Lung-related risk factors include COPD, obesity, and sleep apnea. Other factors include excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis. However, half of cases are not associated with any of these risks. A diagnosis is made by feeling the pulse and may be confirmed using an electrocardiogram (ECG). A typical ECG in AF shows no P waves and an irregular ventricular rate.AF is often treated with medications to slow the heart rate to a near normal range (known as rate control) or to convert the rhythm to normal sinus rhythm (known as rhythm control). Electrical cardioversion can also be used to convert AF to a normal sinus rhythm and is often used emergently if the person is unstable. Ablation may prevent recurrence in some people. For those at low risk of stroke, no specific treatment is typically required, though aspirin or an anti-clotting medication may occasionally be considered. For those at more than low risk, an anti-clotting medication is typically recommended. Anti-clotting medications include warfarin and direct oral anticoagulants. Most people are at higher risk of stroke. While these medications reduce stroke risk, they increase rates of major bleeding.Atrial fibrillation is the most common serious abnormal heart rhythm. In Europe and North America, as of 2014, it affects about 2 to 3% of the population. This is an increase from 0.4 to 1% of the population around 2005. In the developing world, about 0.6% of males and 0.4% of females are affected. The percentage of people with AF increases with age with 0.1% under 50 years old, 4% between 60 and 70 years old, and 14% over 80 years old being affected. A-fib and atrial flutter resulted in 193,300 deaths in 2015, up from 29,000 in 1990. The first known report of an irregular pulse was by Jean-Baptiste de Sénac in 1749. This was first documented by ECG in 1909 by Thomas Lewis.

Browse All Tags